Abstract: Solid dispersions and dosage forms comprising the hydrobromide salt of a diarylpyrimidine derivative, useful as an anti-HIV agent.

Abstract: Provided herein are gel formulations of acyclovir with a low concentration of acyclovir, which can be used, for example, for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The gel formulation can be an aqueous gel formulation, an emulsified gel formulation, or a non-aqueous gel formulation.

Abstract: Nonwoven and elastomeric substrates having formulations disposed thereon, wherein the formulations have improved compatibility with the substrate, are disclosed herein. More particularly, the formulations can be applied on the substrates without compromising the elastomeric properties and overall integrity of the substrate. Laminated articles using one or more of the nonwoven and elastomeric substrates having the formulations disposed thereon are further disclosed.

Abstract: Compositions and methods for treating skin conditions, ailments or diseases, such as autoinflammatory skin diseases such as psoriasis, dermatitis, pyoderma gangrenosum, palmoplantar pustulosis, prurigo nodularis and/or hidradenitis suppurativa, are described. The compositions comprise an agent that modulates the aryl hydrocarbon receptor, in particular an agent that agonizes the receptor. In one embodiment, the agent is indigo or a derivative of indigo, such as indirubin.

Abstract: It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.

Abstract: A process for obtaining an increase in the concentration and/or production of milk protein and/or improving reproductive performance. The process includes administering to a mammal a composition including at least one unsaturated fatty acid, or a derivative thereof, and at least one feed supplement, wherein the combination is administered in an amount such that the mammal absorbs 1 g to 95 g of the at least one unsaturated fatty acid, or the derivative thereof, per day.

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

Abstract: This invention relates to a method for treating atopic dermatitis, comprising administering an effective amount of N-acyltryptamine represented by Formula (I): wherein R represents a saturated aliphatic hydrocarbon group having 2 to 29 carbon atoms; or a pharmaceutically acceptable salt, hydrate or solvate thereof to a subject in need thereof.

Abstract: Provided in the present invention is a use of methyl 4-[9-(6-aminopuryl)]-2(s)-hydroxybutyrate in the preparation of a medicament for treating psoriasis and vitiligo. More specifically, the present invention uses mice whose psoriasis is induced by an imiquimod cream to observe a changing condition in skin lesions on the psoriasis-like mice, according to a psoriasis skin lesion area of the mice and grading standards for disease severity; the present invention also observes a proportion of lymphocytes in the spleens and cytokines in skin lesion tissues of the mice. A good therapeutic effect may be obtained by treating typical cases of vitiligo with an ointment of methyl 4-[9-(6-aminopuryl)]-2(s)-hydroxybutyrate. Results show that methyl 4-[9-(6-aminopuryl)]-2(s)-hydroxybutyrate used in the present invention has a good therapeutic effect on psoriasis and vitiligo, as well as a favorable prospect in clinical application.

Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Abstract: The present invention relates to a thermodynamically stable, biocompatible, environment friendly, and temperature-insensitive microemulsion containing various botanical essential oils, sugar based surfactants, polyhydric alcohols, and an aqueous phase.

Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Abstract: The present invention relates to treatment of a condition associated with hyperinsulinaemia using the compounds described herein.

Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Abstract: The present invention pertains to the use for preventing or treating intestinal infections caused by gram-positive bacteria in animals of an antibacterial compound selected from lactylate in accordance with formula 1, Formula 1 R2-COO—[—CH(CH3)—COO]n—R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate of formula 2, Formula 2: R2-COO—[—CH2-COO]n—R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a lactate ester of formula 3, Formula 3: HO—CH(CH3)—COO—R2 and/or a glycolic acid ester of formula 4, Formula 4: HO—CH2-COO—R2 wherein R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The compound, which preferably is a lactylate or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, is particularly useful in the treatment or prevention of Clostridia. An animal nutrition composition and a method for preventing or treating infections are also claimed.

Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Abstract: The present invention provides formulations and methods for formulation administration that support an individual's body during vaccination and adaptive immune response. The individuals who can benefit from these formulations and methods for formulation administration are infants, children and adults. The formulations comprise ingredients that may be administered prior to, concurrent with or subsequent to the vaccination. The formulations and methods for formulation administration of the present invention preferably act by selectively targeting enzymatic reactions, epigenetic expression, and an individual's various metabolic pathways in support of immune system homeostasis, maintaining balance between oxidative stress and methylation, fostering balance between Th1 and Th2 responses, or a combination thereof, during vaccination and adaptive immune responses to improve vaccine response and reduce vaccine side effects.

Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.